Abstract: The present invention relates to a glycol chitosane derivative, a preparation method thereof and a drug delivery system comprising the same. More specifically, the invention relates to a glycol chitosan derivative, which can form nano-sized self-assembled structures and has both temperature sensitivity and biodegradability so as to be suitable for use as a drug delivery system, as well as a preparation method thereof and a drug delivery system comprising the same.

Abstract: The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.

Abstract: The present disclosure relates to compounds and medical devices activated with a solvophobic material functionalized with a first reactive member and methods of making such compounds and devices.

Abstract: The present disclosure relates to a method of forming fibers. First and second precursors, each possessing a core and at least one functional group known to have click reactivity, are mixed. The mixed precursors are then extruded under heat to cross-link during fiber production.

Abstract: A method for bonding a polymeric fiber to tissue is provided which includes providing a polymeric fiber having a plurality of tissue reactive members linked to a surface of the fiber via a specific binding pair, and contacting the polymeric fiber to biological tissue, to covalently bond the fiber to the tissue.

Abstract: The invention relates to a method for producing an elongate polysaccharide element, in particular a chitosan thread, comprising an operation of extruding an extrusible solution of said polysaccharide through an extrusion die and an operation of coagulating the extruded solution. The extrusible solution is a hydroalcoholic solution containing an alcohol that does not form an azeotrope with water and which has a boiling point of more than 150° C. at atmospheric pressure. The coagulation operation includes a step of evaporating the water, preferably over the alcohol, producing a gelled extruded elongate element in the form of a mainly alcoholic gel, in particular by subjecting the extruded solution to a hot air flow. At least one operation of eliminating the alcohol contained in said gel makes it possible to obtain the elongate polysaccharide element.

Abstract: The present invention relates to methods and compositions for the treatment and/or prevention of diseases such as allergic diseases and inflammatory bowel diseases comprising one or more FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof and optionally one or more non-FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof; as well as the use of such pharmaceutical composition for the prevention and/or treatment of diseases such as allergic diseases and inflammatory bowel diseases. FIBCD1 is herein defined as either a transmembrane receptor, the corresponding DNA or the corresponding mRNA as defined by SEQ ID No. 1, 2 and 3 as well as homologous thereof.

Abstract: Provided are a photosensitizer-metal nanoparticle charge complex and a composition for photodynamic therapy or diagnosis containing the same. The complex includes a metal nanoparticle, a photosensitizer charged with a first charge, and a linker bound to the metal nanoparticle and charged with a second charge having an opposite polarity to the first charge. During circulation in blood, the photosensitizer-metal nanoparticle charge complex is maintained in a complex type, and thus duration of a side effect of photosensitivity can be reduced. In a tumor tissue, the complex is specifically accumulated, but in a normal tissue, it is difficult for the complex to penetrate. Thus, the complex can selectively destroy the tumor tissue. Moreover, selective fluorescence in the tumor tissue can provide further improvement in accuracy of diagnosing a tumor using the complex.

Abstract: The present invention provides a processing method of the natural cellulose fiber with feature for enhancing the capability of antifungi, antibacteria and deodorization. The procedure is that firstly modify and reduce the properties of the natural chitosan of high polymer material to nanometer scale; secondly dunk the chitosan into the syrup-like mixture of wood pulp and NMMO solvent to yield quasi-dope; thirdly dehydrate the quasi-dope of paste mixture to form the mud-like dope; fourthly spin the dope by dryjet wet spinning method; fifthly regenerate the filament in coagulation bath, water rinse and dry; finally water rinse, dry, apply the lubricant to finish. The water soluble chitosan, which has been treated by property modification and reduced to nanometer scale, can effectively and completely solve in the cellulose of low DP to offer wider extent of selection in the DP and better flexibility of adding percentage in content of modified chitosan.

Abstract: Compositions containing lipochitooligosaccharides are disclosed.

Abstract: The present invention provides a method for producing chitin nanofibers, which includes the steps of deproteinizing a material derived from a chitin-containing organism by an alkali treatment, deashing a deproteinized integument by an acid treatment, optionally treating the deashed integument under acidic conditions, and then subjecting to a fiber-loosening treatment. The present invention also provides chitin nanofibers obtained by the method, and a composite material and a coating composition each containing the same. The present invention provides a method for producing chitosan nanofibers, which includes, in addition to the above steps, a deacetylation step and chitosan nanofibers obtained by the method, and a composite material and a coating composition each containing the same.

Abstract: Disclosed is a cross-linked molecularly imprinted polymer including cross-linked chitosan having selective binding sites for phosphate ions, phosphate containing molecules, or a combination of both.

Abstract: A coagulant composition includes chitosan, methacryloyloxyethyltrimethyl ammonium methyl sulfate and a redox initiator. A coagulant, method for making the coagulant and clarifying wastewater is also provided.

Abstract: The invention concerns lake compositions based on natural macromolecules (gelatin, chitosan, pectine etc.) with possible additions of vinyl polymers, metal-alcoxides etc., characterized by a barrier effect modulated in situ, in particular as a function of the relative humidity in the exterior ambient.

Abstract: The present invention relates to a siRNA which targets mRNA of the NF-Kappa B p105 gene to cause its degradation by RNAi induction. In addition, the present invention provides a pharmaceutical composition for the treatment of diseases associated with aberrant cell proliferation and migration, comprising the siRNA and delivery vehicle capable of intracellular delivery of the same.

Abstract: The present invention relates to synthetic compounds that are active on plants, especially as legume nodulation factors, and also as plant growth stimulators, and to methods for preparing such compounds, which are of formula (I).

Abstract: This invention relates to the development of a new method of production of chitin through employment of a microwave process under pressure and/or autoclave with organic acids. This new method eliminates salts and proteins in a single stage and reduces contamination levels. The chitin obtained has application in the areas of medicine, foods, cosmetics and construction, among others.

Abstract: Described herein are composites useful in tissue and organ engineering. In one aspect, the composite comprises the reaction product between a macromolecule comprising at least one thiol group and a gold nanoparticle. The thiolated macro-molecule crosslinks with the gold nanoparticle to produce a composite that is useful in anchoring cells. The composites can be used to form multi-layer 3-D structures, where the cells in each layer can aggregate and fuse with one another to form tissues and organs.

Abstract: Processes for the synthesis of lipochitooligosaccharides were developed. A fully acylated oligoglucosamine precursor is prepared and reacted with a glucosamine monomer that has an amine protecting phthaloyl group. With removal of the phthaloyl group, a fatty acid may be added on the terminal glucosamine unit, forming a lipochitooligosaccharide. The processes can be adapted for use on a commercial scale.

Abstract: Compositions are provided comprising chito-oligomers obtainable from chitin, comprising oligomers of N-acetyl glucosamine (NAG) and glucosamine, wherein at least 50% of the oligomers have a chain length of about 2-50, and the degree of deacetylation of the oligomers is in the range of about 0-70%, preferably about 30-50%. The compositions are highly useful as pharmaceutical compositions for treatment of joint disorders such as rheumatoid arthritis and osteoarthritis. Also provided are methods for treatment of joint disorders and treatment against inflammatory activity.

Abstract: The present invention provides antiviral compositions that comprise one or more of an ionic multivalent metal component, a cationic polymer, and a cationic surfactant. The present invention also provides methods for making and using such antiviral compositions.

Abstract: Hydroxyl polymer-containing compositions, especially hydroxyl polymer-containing compositions that can be processed into polymeric structures, especially polymeric structures in the form of fibers are provided.

Abstract: An activatable functionalised Nth generation dendrimer having: a core comprising a first monomer having at least two carboxylic acid functional groups; and N successive generations, where N=0 to 10, wherein each generation comprises: a second monomer having at least two alcohol functional groups, wherein at least one alcohol group is bonded to a carboxylic acid group of the first monomer of the prior generation, and an additional first monomer attached to a second alcohol function group of said second monomer of that generation; and the final generation having attached thereto at said second alcohol functional group of said second monomer, a moiety having a dicarboxylic acid functional group, activatable by treatment with a carboxylic acid activating reagent such that reactivity of the carboxylic acid functional group is increased. The dendrimer, when activated, may be used in applications such as polymer crosslinking and/or nanoshell production.

Abstract: The present invention relates to synthetic compounds that are active on plants, especially as legume nodulation factors, and also as plant growth stimulators, and to methods for preparing such compounds, which are of formula (I).

Abstract: According to one embodiment, the disclosure provides a delivery formulation including a chitosan in which the primary amines are partially modified with 4-imidazole acetic acid monohydrochloride and a therapeutic or imaging material. According to another embodiment, the disclosure provides a method for delivering a material to an epithelial or mucosal tissue comprising increasing the permeability of an epithelial or mucosal tissue by applying to said tissue a delivery formulation including a chitosan in which the primary amines are partially modified with 4-imidazole acetic acid monochlorohydride and a therapeutic or imaging material.

Abstract: This invention provides a method capable of easily determining with high accuracy a protein in chitosan, said protein having a potential relevance to the development of an allergy, specifically tropomyosin and the content of the peptide. According to the method, tropomyosin is determined by immunoassay with the chitosan being in a state dissolved in an aqueous solution of an organic acid. The present invention also provides chitosan, which has a measurement value of the protein, specifically tropomyosin not higher than a predetermined value as measured by the determination method and is assessed to have only a low risk of inducing the allergy.

Abstract: The present invention provides for curcumin nanoparticles and curcumin bound to chitosan nanoparticles and methods of producing the same. Bioavailability of curcumin in these formulations was shown to improve by more than 10 fold.

Abstract: Provided herein are water-soluble carbohydrate polymers which are monoderivatized at their reducing terminus, such that the carbohydrate polymers can be selectively conjugated at a single location. Also provided are methods of preparation and conjugation of the monoderivatized carbohydrate polymers.

Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.

Abstract: The present disclosure relates to a method for the sustained release of a drug, comprising the steps of: (a) preparing a biocompatible polymer having a hydrophobic group conjugated to the biocompatible polymer; and (b) contacting the biocompatible polymer to the drug for adsorbing the drug to the hydrophobic group of the biocompatible polymer, thereby obtaining a drug delivery carrier for the sustained release of the drug; wherein the drug is a protein, a peptide or a non-hydrophilic chemical drug; wherein when the drug adsorbed to the hydrophobic group of the biocompatible polymer is administered to a mammal, it shows a sustained release profile in the mammal. The drug delivery carrier according to the present disclosure having the hydrophobic group conjugated to the biocompatible polymer may be useful for adsorption of synthetic drugs having very low solubility in water.

Abstract: Methods of identifying Crohn's disease patients who may require early surgery and/or who are susceptible to developing complications during the course of disease. Anti-laminarin (anti-L) and anti-chitin (anti-C) antibodies, both independently and combined, can serve as diagnostic and prognostic indices for Crohn's disease.

Abstract: Manufactured hyaluronic acid products are used in numerous surgical applications including viscoelastic supplementation for the treatment of osteoarthritis, however, traditional sterilization techniques result in the breakdown of such high molecular weight viscoelastic biopolymers and are thus unsuitable. Disclosed are processes for obtaining concentrated sterile solutions of high molecular weight biopolymers such as hyaluronic acid. The processes include filter sterilization with a dilute preparation of the biopolymer, and concentration of the dilute filter sterilized biopolymer by ultrafiltration to a desired concentration.

Abstract: The present invention relates to a chitosan capsule in which a soluble active ingredient is encapsulated in a matrix containing chitosan and phytic acid; a cross-linking method and materials capable of being used in preparing the capsule; and pharmaceutical, food and cosmetic compositions comprising the capsule. The chitosan capsule according to the present invention is prepared via ionic gelation of chitosan as a biodegradable polymer with phytic acid capable of rapidly and effectively forming a cross-linking reaction with the chitosan polymer. The capsule of the present invention shows high encapsulation efficiency for a soluble active ingredient and protects the soluble active ingredient from being damaged in a digestive tract, resulting in improving an in vivo delivery efficiency of a physiologically active material.

Abstract: The present invention provides a PEGylated and fatty acid grafted chitosan oligosaccharide comprising a structural unit represented by the following Formula (I) and a structural unit represented by the following Formula (II) and synthesize method, wherein the chitosan oligosaccharide has a molecular weight of less than 200,000 Da, and a degree of deacetylation of 70%-100%, and part of free amino groups of chitosan oligosaccharide chain are replaced by a fatty acid or PEG, where n refers to degree of polymerization of the PEG, and R is an alkyl group having 11-21 carbon atoms. The grafting ratio of fatty acids is 1%-50%, and the grafting ratio of PEG is 0.05%-50%. The present invention also comprise a pharmaceutical composition comprising the PEGylated and fatty acid grafted chitosan oligosaccharide as a carrier, and use of the PEGylated and fatty acid grafted chitosan oligosaccharide in preparation of a pharmaceutical composition.

Abstract: This invention concerns a manufacturing process for nanoparticles composted of biodegradable polymers and active ingredients with therapeutic, cosmetic, veterinary, and alimentary applications, and a composition which contains said nanoparticles, which are used in products for animals, including humans. The process consists of emulsifying the hydrosoluble substances to form a w/o emulsion; dissolving the non-emulsionable substances, liposoluble polymer or polymer/compounds in organic solvents; mixing the w/o emulsion and the organic solution of the hydrophobics to form a pre-emulsioned mixture; adding the pre-emulsioned mixture, with the assistance of an injector system, to an aqueous emulsifier solution under ultradispersion to form the final emulsion; leading the final emulsion to evaporation, then centrifuge, freeze, and lyophilize.

Abstract: The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan.

Abstract: The invention relates to nucleic acid molecules selected from the group comprising: a) nucleic acid molecules that code for a form of the polypeptide with the derived amino acid sequence according to SEQ ID No. 3, said polypeptide having a deacetylase activity; b) nucleic acid molecules that comprise the nucleotide sequence according to SEQ ID No. 1 or SEQ ID No.

Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.

Abstract: The present invention relates to a biofabricated Active Microfluidic Membrane (AMM) in a microfluidic network of a microfluidic device and a method for the in situ biofabrication of such a microfluidic network. More specifically, the invention relates to devices exhibiting (and methods of) positioning (i.e., erecting, modifying or removing a membrane matrix in situ in a microchannel of a microfluidic network of a microfluidic device. In one embodiment, the membrane comprises a single type of matrix constituent, such as chitosan, alginate, etc. Alternatively, the membrane may be composed of two or more matrix constituents, which may be integrated into one another or layered adjacent to one another.

Abstract: The subject invention provides silica-based material that has high affinity to chitin, chitin derivatives and chitin-containing microorganisms at an acidic pH. In an embodiment, the silica-based material surface comprises glass. Also provided are methods for preparing the subject silica-based chitin-binding material. In addition, the subject invention provides rapid, specific, sensitive, accurate and convenient methods for detection, isolation and purification of chitin, chitin derivatives and chitin-containing microorganisms.

Abstract: The present invention relates to a water soluble chitosan nanoparticle (WSC-NP) for delivering an anticancer agent and a preparing method thereof, more precisely, a water soluble chitosan nanoparticle for delivering an anticancer agent which has function of targeting on a wanted area by introducing a functional group in the location of highly reactive amine group and becomes an excellent gene carrier with the use of water soluble chitosan since the water soluble chitosan itself can combined with DNA having a negative electric charge(?) owing to the very strong positive electric charge(+) of its amine group, and a preparing method thereof. Therefore, a water-soluble chitosan nanoparticle for delivering an anticancer agent of the present invention can effectively envelope paclitaxel by introducing hydrophilic and hydrophobic groups in the position of highly reactive amine group of the water-soluble chitosan.

Abstract: A method of homogeneously forming functionalized biocompatible oligomers includes the steps of dissolving a biocompatible oligomer in a solvent to form a solution, and admixing at least one ? complex forming group to the solution, wherein the ? complex forming group grafts to at least one location on the backbone of the oligomer to form a grafted oligomer. The oligomer is preferably oligochitosan and the solvent is preferably dimethylsulfoxide (DMSO). The degree of graft substitution can be at least 50%. The functionalized biocompatible oligomer can be used for drug detoxification through binding to a variety of target drugs.

Abstract: A method of making ultra-small chitosan nanoparticles having a size range of approximately 10-20 nm, includes preparing a first microemulsion containing effective amounts of cyclohexane, n-hexanol, chitosan polymer and a nonionic surfactant. A second microemulsion is prepared containing effective amounts of cyclohexane, n-hexanol, tartaric acid, EDC, n-hydroxysuccinimide, and a nonionic surfactant. The method continues by reacting the first and second microemulsions for a time sufficient to form the ultra-small chitosan nanoparticles and recovering the nanoparticles from the reacted microemulsion. The chitosan polymer may be crosslinked and may also be tagged with a fluorescent compound, a radio-opaque compound, a paramagnetic ion, a ligand specific for a predetermined biologic target, a drug, and combinations thereof.

Abstract: A new class of polymeric additives for papermaking is disclosed as well as a process for their manufacture, a method for their use and a paper sheet containing the addition. The additives can be used in paper manufacture as agents for improving retention, paper machine operation and the strength properties of the product. The additives are manufactured from a microbial biomass. The biomass that contains acetyl amino groups or other amides is chemically modified by hydrolysis of the amides to form primary amino groups. Under neutral or acidic conditions these primary amines become cationic, which assures a good absorption of the additive onto fibres and fines of pulp that is generally of anionic nature.

Abstract: Non-crosslinked derivatives of oligo/polysaccharides of formula I, wherein: X is OH, OM, NH—R1, O—R1; M is an alkaline or alkaline-earth metal, transition metal, or cation containing a quaternary nitrogen atom; Y is H or R2; R1: the residue of an oligo/polysaccharide; R2: the residue of a C1-C4 linear chain aliphatic carboxylic acid or citric acid; provided that at least one X is NH—R1 or O—R1, while the other two X are present in acid (OH) or salified form (OM).

Abstract: The present disclosure provides compositions for enhanced delivery of therapeutic agents. Drug delivery vehicle compositions may include a modified polysaccharide (e.g. chitosan) having at least one secondary amine or at least one tertiary amine and a therapeutic agent such as a therapeutic nucleic acid and/or a therapeutic anionic agent. Various additional modifications of a modified polysaccharide of the disclosure are also described. Exemplary therapeutic agents may include but are not limited to nucleic acids, polynucleotides, siRNA and/or pDNA. Compositions of the disclosure may be formulated as nanoparticles and may provide one or more advantages including efficient transfection, bio-delivery, availability, buffering ability, serum stability. Methods for synthesizing the drug delivery compositions are also set forth. The disclosure also provides methods for delivering/administering therapeutic agents using the drug delivery compositions of the disclosure to a patient in need thereof.

Abstract: The invention relates to a medical material, especially to a hemostatic and wound-healing water-soluble chitosan-based fiber material. The water-soluble chitosan-based fiber material comprises carboxymethyl chitosan fiber, hydroxypropyl chitosan fiber, hydroxyethyl chitosan fiber, carboxymethyl hydroxyethyl chitosan fiber or mixtures thereof.

Abstract: The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.

Abstract: The present invention relates to novel quaternized polymers, especially of chitin/chitosan type, and to carbohydrate polymers carrying quaternized ammonium groups, especially piperazinium groups. Such polymers are characterized i.a. by improved solubility characteristics.

Abstract: The invention provides a hydrogel suitable for use in wound healing, particularly for reducing post-surgical adhesions. The hydrogel comprises cross-linked derivatives of chitosan and dextran polymers. The hydrogel forms when solutions of the polymers are combined.